D-0539-2020 Class II Ongoing
FDA drug recall D-0539-2020 was initiated by Sanofi-Aventis U.S. LLC on Oct 22, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 11, 2019
- Initiation Date
- Oct 22, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Maximum Strength Zantac 150 mg, Distributed by: Chattem, Inc., a Sanofi Company P.O. Box 2219, Chattanooga, TN 37409-0219. NDC's: 0597-0121-01, 0597-0121-06, 0597-0121-08, 0597-0121-09, 0597-0121-11, 0597-0121-24, 0597-0121-38, 0597-0121-50, 0597-0121-64, 0597-0121-66, 0597-0121-68, 0597-0121-78, 0597-0121-80, 0597-0121-82, 0597-0121-85, 0597-0121-90, 0597-0121-94.
Reason for recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Distribution pattern
Nationwide
Code information
all lots
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0539-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026